Fibrosis
Disease State Hub
Featured
10/05/2026
Ashton L. Stahl
A multinational study examined clinical outcomes and noninvasive fibrosis testing in patients with lean metabolic dysfunction–associated steatotic liver disease vs. those with overweight or obesity.
10/05/2026
08/25/2025
Kate Young
The FDA has announced the approval of the semaglutide injection to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis following promising interim analysis data.
...
08/25/2025
08/22/2025
Anthony Calabro, MA
Metabolic dysfunction–associated steatohepatitis is becoming increasingly common in patients with type 2 diabetes and other metabolic risk factors. Test your knowledge of the key diagnostic features,...
08/22/2025
Interactive Features
08/22/2025
Anthony Calabro, MA
Metabolic dysfunction–associated steatohepatitis is becoming increasingly common in patients with type 2 diabetes and other metabolic risk factors. Test your knowledge of the key diagnostic features,...
08/22/2025
01/03/2020
Think you know the main pathophysiologies of inflammation that lead to irreversible fibrosis? Take our quick quiz and find out!
01/03/2020
Clinical Insights
05/11/2018
Yelena Havryliuk, MD, FACOG, Assistant Professor of Obstetrics and Gynecology at Weill Cornell Medical College, describes the Acessa treatment for uterine fibroids and why it might be better than other...
05/11/2018
